Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) is a treatment option for somatostatin receptor–positive, unresectable or metastatic neuroendocrine tumors (NETs). Despite high disease control rates seen with PRRT, a subset of the NET population seems to have a short progression-free interval. We hypothesize that patients with NETs with rapid progression post-PRRT may have mixed low- and high-grade cell populations, and PRRT treats the lower-grade component, allowing the more aggressive high-grade component to progress.
Source: Pancreas - Category: Gastroenterology Tags: Case Report Source Type: research